Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7452W HIGH $8.50
Volume
1.49 M
Value Traded
4.50 M
Short % Float
9.65%
Days to Cover
5.3
+8.66%Week
+41.98%1 Month
+13.16%3 Month
+24.38%6 Month
-86.24%5 Year
-17.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
575.81 M
EPS (TTM)
-1.18
P/E Ratio
-
Ent. Value
581.31 M
Total Shares
95.69 M
Float Shares
88.60 M
Insiders
7.37%
Institutions
94.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MYGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Myriad Genetics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Myriad Genetics, Inc.
1362Total events
9Upcoming
284Tier-1 (high impact)
2009 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
Proffered paper presentation of ultrasensitive ctDNA MRD data in resectable colorectal cancer at ESMO 2026
resectable colorectal cancersource ↗
◆Poster PresentationPresentation
Poster presentation of WGS-based ctDNA MRD initial findings in resectable pancreatic cancer at ESMO 2026
resectable pancreatic cancersource ↗
▲AcquiredCorporate
Myriad enters definitive agreement to sell Prenatal Health testing business (Prequel, Foresight, SneakPeek, FirstGene) to Labcorp for $210M
▲Partnership / LicenseCorporate
Myriad Genetics and SOPHiA GENETICS announce collaboration to advance PrGIS technology with AstraZeneca
prostate cancersource ↗
▲Product LaunchPost-Market
Full commercial launch of FirstGene Multiple Prenatal Screen
prenatal genetic screeningsource ↗
●FDA Filing AcceptedRegulatory Filing
Submitted Precise MRD breast to MolDX for coverage determination
breast cancersource ↗
▲PublicationProlarisFiledPresentation
Published largest individual-patient-data meta-analysis of Prolaris
prostate cancersource ↗
▲Product LaunchFirstGenePost-Market
Launched FirstGene Multiple Prenatal Screen
prenatal screeningsource ↗
●Enrollment UpdateTrial
CONNECTOR study continues to progress in enrollment
prenatal screeningsource ↗
●Enrollment UpdateFirstGeneTrial
CONNECTOR study continues to progress in enrollment
prenatal screeningsource ↗
▲Product LaunchPost-Market
Expanded availability of Precise MRD for breast, colorectal and renal cancers
breast, colorectal and renal cancerssource ↗
▲PublicationPresentation
Publication of MONITOR-Breast study results in Future Oncology
breast cancersource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Poster PresentationPresentation
Poster 270: Use of ctDNA to Stratify Risk of Recurrence After Surgical Debulking in Epithelial Ovarian Cancer
Epithelial Ovarian Cancersource ↗
◆Poster PresentationPresentation
Poster 501: Association between physical activity and MRD clearance in postoperative cancer patients
Postoperative Cancersource ↗
▲PublicationPresentation
Analytical validation published in Clinical Chemistry
prenatal genetic screeningsource ↗
●Enrollment UpdateFirstGeneTrial
CONNECTOR study continues enrollment progress
prenatal screeningsource ↗
▲Oral PresentationPresentation
Presented data at ASCO Annual Meeting including MONSTAR-SCREEN-3 interim outcomes
multiple cancerssource ↗
◆Oral PresentationPresentation
Industry Expert Theater: Introduction to Precise MRD Test by Dale Muzzey
Multiple Solid Tumorssource ↗
◆Poster PresentationPresentation
Poster 64: Whole-Genome Sequencing-Based Ultra-sensitive ctDNA MRD Assessment in Resectable Gastric Cancer
Gastric Cancersource ↗
▲Oral PresentationPresentation
Presented data at ASCO Annual Meeting including MONSTAR-SCREEN-3 interim outcomes
multiple cancerssource ↗
◆Poster PresentationPresentation
Poster: A pragmatic study of the clinical utility of genomic classifiers in guiding prostate cancer treatment decisions (PROMPT-Bx)
prostate cancersource ↗
◆Oral PresentationPresentation
Podium presentation of early findings from MONITOR-Breast: ctDNA dynamics during neoadjuvant therapy using Precise MRD
breast cancersource ↗
◆Oral PresentationPresentation
Podium presentation of phase II trial of adjuvant PD-1 blockade with endocrine therapy in HR+ inflammatory breast cancer
inflammatory breast cancersource ↗
◆Poster PresentationPresentation
Poster: Analytical validation of an ultra-high sensitivity tumor-informed MRD assay
breast cancersource ↗
◆Poster PresentationPresentation
Poster: Independent validation of polygenic risk scores for overall and triple-negative breast cancer among high-risk African American women
breast cancersource ↗
◆Oral PresentationPresentation
Exhibitor Spotlight Theater: Advances in ctDNA Testing towards Biopharma Development & Clinical Dx
▲Other Regulator MilestoneEx-US Regulatory
MHLW approved MyChoice Test as companion diagnostic for Lynparza in prostate cancer
prostate cancersource ↗
◆Oral PresentationPresentation
Age at ovarian cancer diagnosis varies by lynch syndrome gene: a genetic testing laboratory registry study
ovarian cancersource ↗
◆Poster PresentationPresentation
Evaluation of the Relationship of Molecular Residual Disease Testing to Ovarian Cancer Recurrence
ovarian cancersource ↗
◆Poster PresentationPresentation
Broad landscape of genetic variants and ancestry associated with ovarian cancer before age forty
ovarian cancersource ↗
◆Oral PresentationPresentation
Prevalence of germline pathogenic variants in patients with endometrial cancer diagnosed before and after 65 years old within a laboratory-based research registry
endometrial cancersource ↗
▲Product LaunchProlarisFiledPost-Market
Full commercial launch of AI-enabled Prolaris prostate cancer test in partnership with PATHOMIQ expected in Q2 2026
prostate cancersource ↗
▲Product LaunchProlarisFiledPost-Market
Launched Prolaris + AI for prostate cancer
prostate cancersource ↗
▲Product LaunchPost-Market
Expanded Precise MRD to include colorectal and renal cancers
colorectal and renal cancerssource ↗
▲PublicationPresentation
MONITOR-Breast study results published in Future Oncology
breast cancersource ↗
●Restructuring LayoffsCorporate
Activated Ascend initiative to increase efficiency and scalability
▲FDA ApprovalFDA Decision
FDA approval of MyChoice CDx Test as companion diagnostic for Zejula
advanced ovarian cancersource ↗
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare conference 1-on-1 meetings
▲Product LaunchPost-Market
Limited commercial launch of Precise MRD test with select community oncologists for breast cancer
breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How MYGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Myriad Genetics, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MYGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Precise MRD | various cancer types | 2026-05-27 | 97% baseline detection rate; 16% of samples detected in the ultrasensitive rangeRead More | Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kumar RashmiDirector | Sell | -15,000 171,889 held | $4.46 | 06/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MYGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2.4 % | 122.88 M | - |
MYGN Institutional Ownership Trends
MYGN Short Interest
Shares sold short, counted twice a month.
9.65%
Short % of Float
of tradable shares sold short
9.3M
Shares Sold Short
+8.4% vs prior count
5.3 High
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MYGN ranks across every disease it competes in
Competitive Position is a premium feature
See how MYGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMYGN News
MYGNMyriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Myriad Genetics reported MONSTAR-SCREEN-3 data showing its Precise MRD platform detects recurrence in colorectal and pancreatic cancers. ctDNA appeared four months before clinical signs in colorectal cases. The study highlights ultra-sensitive detection capabilities. Myriad will present these findings at ESMO Congress 2026.
Read more →MYGN▲ +31.6%on this newsshared move
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Myriad Genetics has entered a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million. This strategic move aims to enhance Myriad's revenue and profitability while providing Labcorp with expanded access to innovative testing solutions. The transaction is expected to close by early 2027, pending regulatory approval.
Read more →MYGN▼ -8.5%on this news· ran to +28% by day 3shared move
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Myriad Genetics, Inc. will announce its third quarter 2026 financial results on November 4, 2026. The earnings call is scheduled for 4:30 pm ET, where management will discuss the company's performance. A live webcast will be available, and an archived version will be accessible afterward. Myriad Genetics focuses on molecular diagnostic testing and precision medicine.
Read more →MYGNMyriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Myriad Genetics and SOPHiA GENETICS have announced a collaboration to advance the prostate genomic instability score (PrGIS) technology, enhancing precision oncology approaches. This partnership aims to support clinical trials and improve access to precision oncology medicines. Myriad's proprietary MyChoice CDx test will produce the PrGIS score, now being developed for prostate cancer. The collaboration also includes plans for presenting research at the upcoming ESMO Congress 2026.
Read more →MYGNMyriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics has appointed Vishal Sikri as Executive Vice President - Commercial, effective September 16, 2026. Sikri, previously SVP of Product, brings extensive experience in molecular diagnostics and oncology. His leadership is expected to enhance Myriad's focus on cancer care and support profitable growth. The company has also reaffirmed its financial guidance for the full year 2026.
Read more →MYGNMyriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
Myriad Genetics, Inc. will present at the 21st Annual Wells Fargo Healthcare Conference on September 10, 2026. The presentation will be available via a live audio webcast. Myriad is known for its contributions to molecular diagnostic testing and precision medicine, aiming to improve patient care through genetic insights.
Read more →MYGN▼ -46.7%on this news
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Myriad Genetics reported its second quarter 2026 financial results, revealing an 11% decrease in revenue year-over-year to $190.7 million. Despite challenges in Prenatal Health and payer friction affecting average revenue per test, the company noted a 6% growth in test volumes within its Cancer Care Continuum business. Myriad has initiated new strategies to enhance efficiency and profitability, while also revising its financial guidance for the remainder of 2026.
Read more →MYGNMyriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
Myriad Genetics will release its second quarter 2026 financial results on July 30, 2026. The earnings conference call is scheduled for 4:30 pm ET, where management will discuss the company's performance. A live webcast will be available, and an archived version will be accessible afterward.
Read more →MYGNMyriad Genetics Launches FirstGene® Multiple Prenatal Screen
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a comprehensive test that performs four prenatal genetic screens from a single blood draw as early as eight weeks gestation. This innovative test boasts high analytical sensitivity and specificity, providing clinicians with timely insights to support informed decision-making during pregnancy. The FirstGene screen aims to streamline the prenatal screening process, enhancing patient care.
Read more →MYGNNew Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad Genetics announced a large-scale meta-analysis demonstrating that the Prolaris Biopsy Test provides significant prognostic information for localized prostate cancer. The study, involving 8,478 patients, showed that the test enhances risk stratification beyond conventional methods. This could help clinicians make informed decisions regarding patient management strategies, including active surveillance and treatment escalation.
Read more →MYGNMyriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics has announced the expanded availability of its Precise MRD test for breast, colorectal, and renal cancers, significantly increasing access for patients. The test utilizes whole-genome sequencing to provide detailed insights into disease status and treatment response. A recent publication from the MONITOR-Breast study further validates its effectiveness in monitoring ctDNA during therapy. This expansion aligns with Myriad's strategy to enhance precision oncology.
Read more →MYGNMyriad Genetics Names Raj Jampa as New Chief Technology Officer
Myriad Genetics has appointed Raj Jampa as the new Chief Technology Officer, effective June 1, 2026. Jampa, who has a strong background in technology leadership, will focus on enhancing the company's digital technology and AI capabilities to support its growth strategy. His experience includes roles at Agilent Technologies and Exact Sciences, where he led significant technology transformations.
Read more →MYGNMyriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Myriad Genetics, Inc. showcased data regarding its Precise MRD assay at the 2026 ASCO Annual Meeting, presented through six posters highlighting its applications in various cancer types. Key findings from the MONSTAR-SCREEN-3 study revealed a 97% baseline detection rate and significant correlations between ctDNA positivity and disease-free survival. The presentations emphasized the prognostic capabilities of the assay, which can aid in earlier clinical decision-making and progression monitoring in cancer treatment. Experts from Myriad will provide additional insights during a session at the conference.
Read more →MYGNMyriad Genetics Launches Prolaris + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Myriad Genetics has announced the launch of the Prolaris + AI Test, the first prostate cancer biomarker test that integrates clinical-pathological features with AI-powered digital pathology. This innovative approach aims to better identify patients eligible for active surveillance and personalize their treatment plans. The test is based on data from longitudinal studies and provides doctors with a single report that combines critical risk assessments. The Prolaris + AI Test is set to be available starting May 29, 2026, for U.S. samples, excluding New York State, with further approvals anticipated soon.
Read more →MYGNActress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Actress Jackie Tohn has partnered with Myriad Genetics to promote hereditary cancer testing after discovering she carries a BRCA1 gene variant. Following her father's cancer diagnosis, she underwent a prophylactic double mastectomy. Tohn emphasizes the importance of genetic testing for individuals with a family history of cancer, particularly for those of Ashkenazi Jewish descent.
Read more →MYGNMyriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, a leader in molecular diagnostics, will participate in two upcoming healthcare conferences: the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The investor meetings and presentations aim to enhance stakeholder engagement and demonstrate the company's commitment to advancing healthcare through genetic insights. Attendees can access the Goldman Sachs presentation via a live audio webcast on the company's website.
Read more →MYGN▼ -18.3%on this newsshared move
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Myriad Genetics reported its Q1 2026 financial results, highlighting strong performance in its Cancer Care Continuum business with revenues of $120.2 million. The company reaffirmed its financial guidance for 2026, indicating confidence in growth driven by new product launches, including the Precise MRD test for breast cancer. However, it also reported a cash outflow of $13.4 million, raising concerns about operational costs.
Read more →MYGNMyriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
A nationwide survey conducted by Myriad Genetics reveals strong patient support for personalized mental health care, with 88% of participants indicating greater confidence in treatment if tailored to their needs. The survey highlights significant dissatisfaction with current mental health care, where many feel treatments are overly standardized. Furthermore, a majority of respondents expressed a desire for more individualized treatment approaches and indicated low awareness of genetic testing options that could improve their medication management. The findings suggest a critical opportunity for enhanced patient care through personalized mental health strategies, as represented by the GeneSight Test.
Read more →MYGNMyriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Myriad Genetics, a leader in molecular diagnostics, will announce its first quarter 2026 financial results on May 5, 2026. The earnings call is scheduled for 4:30 PM ET, where management will discuss the company's performance. A live webcast will be available on their Investor Relations website.
Read more →MYGNMyriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
Myriad Genetics announced it will present six abstracts, including two podium presentations, at the AACR Annual Meeting 2026. The focus will be on its Precise MRD assay and the results from the MONITOR-Breast study, which evaluates ctDNA dynamics during neoadjuvant therapy in breast cancer patients. These presentations aim to provide insights that could help personalize treatment decisions and address challenges in assessing patient responses to therapy.
Read more →About Myriad Genetics, Inc.
Headquarters322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
BIOPHARMAWATCH ELITE PLUS
Trade the next MYGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime